All In Biotech

Drug Trial Radar · NCT03180307

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Feb 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Jan 26, 2018

Primary completion

Apr 16, 2020

Study completion Oct 16, 2020

Sponsor

Lead sponsor
On Target Laboratories, LLCIndustry
Sponsor type
Industry
Collaborators
SynteractHCR
First posted
Jun 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery.

Conditions

  • Ovarian Cancer

Interventions

  • OTL38Drug

    0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes

  • near infrared camera imaging systemDevice

    Infrared imaging used to excite OTL38 for fluorescence

  • laparotomyProcedure

    primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Patient LevelTime frame: 30 days

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • The Mayo Clinic - Phoenix

    Phoenix, Arizona

  • University of Arizona

    Tucson, Arizona

  • City of Hope Medical Center

    Duarte, California

  • University of CA at Irvine Chao Cancer Center

    Orange, California

  • Moffitt Cancer Center

    Tampa, Florida

  • Karmanos Cancer Institutes

    Detroit, Michigan

  • Mayo Clinic-Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Kettering Medical Center

    Kettering, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Leiden University Medical Center

    Leiden, South Holland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.